Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash from Financing Activities (2024 - 2025)

Historic Cash from Financing Activities for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$5000.0.

  • Prelude Therapeutics' Cash from Financing Activities rose 9618.32% to -$5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$162000.0, marking a year-over-year change of. This contributed to the annual value of -$120000.0 for FY2024, which is 10008.8% down from last year.
  • Prelude Therapeutics' Cash from Financing Activities amounted to -$5000.0 in Q3 2025, which was up 9618.32% from $37000.0 recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Cash from Financing Activities ranged from a high of $59000.0 in Q2 2024 and a low of -$160000.0 during Q1 2025